Literature DB >> 21983903

Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study.

Khalid Seghrouchni1, Christian van Delden, Dennis Dominguez, Mohamed Benkabouche, Louis Bernard, Mathieu Assal, Pierre Hoffmeyer, Ilker Uçkay.   

Abstract

PURPOSE: Osteoarticular infections due to methicillin-susceptible Staphylococcus aureus (MSSA) or its methicillin-resistant variant (MRSA) are feared due to treatment failures. According to clinical experience, Pseudomonas aeruginosa may reveal less long-term remission than S. aureus.
METHODS: A case-controlled study comparing outcomes of osteoarticular infections due to P. aeruginosa vs S. aureus was performed at Geneva University Hospitals.
RESULTS: A total of 111 S. aureus (including 37 MRSA) and 20 P. aeruginosa osteoarticular infections were analysed in 131 patients: arthroplasties (n = 38), fracture fixation devices (n = 56), native joint arthritis (n = 7) and osteomyelitis without implant (n = 30). The median active follow-up time was 4 years. The patients underwent a median number of two surgical interventions for P. aeruginosa infections compared to two for S. aureus (two for MRSA), while the median duration of antibiotic treatment was 87 days for P. aeruginosa and 46 days for S. aureus infections (58 days for MRSA) (all p > 0.05). Overall, Pseudomonas-infected patients tended towards a lower remission rate than those infected with S. aureus (12/20 vs 88/111; p = 0.06). This was similar when P. aeruginosa was compared with MRSA alone (12/20 vs 30/37; p = 0.08). In multivariate logistic regression analyses adjusting for case mix, odds ratios (OR) for remission were as follows: P. aeruginosa vs S. aureus [OR 0.4, 95% confidence interval (CI) 0.1-1.2], number of surgical interventions (OR 0.6, 95% CI 0.5-1.0) and duration of antibiotic treatment (OR 1.0, 95% CI 1.0-1.0).
CONCLUSIONS: Despite a similar number of surgical interventions and longer antibiotic treatment, osteoarticular infections due to P. aeruginosa tended towards a lower remission rate than infections due to S. aureus in general or MRSA in particular.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983903      PMCID: PMC3337090          DOI: 10.1007/s00264-011-1366-8

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  38 in total

Review 1.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

2.  Recurrent osteomyelitis caused by infection with different bacterial strains without obvious source of reinfection.

Authors:  Ilker Uçkay; Mathieu Assal; Laurence Legout; Peter Rohner; Richard Stern; Daniel Lew; Pierre Hoffmeyer; Louis Bernard
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

3.  Results of periprosthetic hip and knee infections caused by resistant bacteria.

Authors:  Douglas J Kilgus; David J Howe; Andrew Strang
Journal:  Clin Orthop Relat Res       Date:  2002-11       Impact factor: 4.176

4.  Pseudomonas arthritis treated with parenteral and intra-articular ceftazidime.

Authors:  K Walton; R C Hilton; R A Sen
Journal:  Ann Rheum Dis       Date:  1985-07       Impact factor: 19.103

5.  Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli.

Authors:  D N Gilbert; A D Tice; P K Marsh; P C Craven; L C Preheim
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis.

Authors:  A J Lesse; C Freer; R A Salata; J B Francis; W M Scheld
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

7.  Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.

Authors:  R N Greenberg; D J Kennedy; P M Reilly; K L Luppen; W J Weinandt; M R Bollinger; F Aguirre; F Kodesch; A M Saeed
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  Clinical presentation and management of Pseudomonas osteomyelitis.

Authors:  S J Elliott; S C Aronoff
Journal:  Clin Pediatr (Phila)       Date:  1985-10       Impact factor: 1.168

9.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

10.  Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  H Giamarellou; N Galanakis; C Dendrinos; J Stefanou; E Daphnis; G K Daikos
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  16 in total

1.  A selected screening programme was less effective in the detection of methicillin-resistant Staphylococcus aureus colonisation in an orthopaedic unit.

Authors:  Jayshree Dave; Paul J Jenkins; Alison Hardie; Melvyn Smith; Paul Gaston; Alan P Gibb; Kate Templeton; Alastair H Simpson
Journal:  Int Orthop       Date:  2013-09-08       Impact factor: 3.075

2.  Chronic osteomyelitis.

Authors:  Ilker Uçkay; Kheeldass Jugun; Axel Gamulin; Joe Wagener; Pierre Hoffmeyer; Daniel Lew
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

3.  Conservative Therapy is an Effective Option in Patients With Localized Infection After Penile Implant Surgery.

Authors:  Mohamad Habous; Mohammed Farag; Ben Williamson; Osama Laban; Saad Mahmoud; Osama Abdelwahab; Mohamed Elkhouly; Usama Kamil; Saleh Binsaleh; Raanan Tal; David Ralph; John P Mulhall
Journal:  J Sex Med       Date:  2016-05-06       Impact factor: 3.802

4.  Antibacterial activity of oxyresveratrol against methicillin-resistant Staphylococcus aureus and its mechanism.

Authors:  Dae-Ki Joung; Su-Hyun Mun; Sung-Hoon Choi; Ok-Hwa Kang; Sung-Bae Kim; Young-Seob Lee; Tian Zhou; Ryong Kong; Jang-Gi Choi; Dong-Won Shin; Youn-Chul Kim; Dong-Sung Lee; Dong-Yeul Kwon
Journal:  Exp Ther Med       Date:  2016-06-27       Impact factor: 2.447

5.  Remission rate of implant-related infections following revision surgery after fractures.

Authors:  Mohamed Al-Mayahi; Michael Betz; Daniel A Müller; Richard Stern; Phedon Tahintzi; Louis Bernard; Pierre Hoffmeyer; Domizio Suvà; Ilker Uçkay
Journal:  Int Orthop       Date:  2013-09-20       Impact factor: 3.075

6.  Single-stage treatment of infected tibial non-unions and osteomyelitis with bone marrow granulocytes precursors protecting bone graft.

Authors:  Philippe Hernigou; Arnaud Dubory; Yasuhiro Homma; Charles Henri Flouzat Lachaniette; Nathalie Chevallier; Helene Rouard
Journal:  Int Orthop       Date:  2017-11-13       Impact factor: 3.075

7.  Increased risk of joint failure in hip prostheses infected with Staphylococcus aureus treated with debridement, antibiotics and implant retention compared to Streptococcus.

Authors:  Michael Betz; Sophie Abrassart; Pierre Vaudaux; Ergys Gjika; Maximilian Schindler; Julien Billières; Besa Zenelaj; Domizio Suvà; Robin Peter; Ilker Uçkay
Journal:  Int Orthop       Date:  2014-09-04       Impact factor: 3.075

8.  Coating with a novel gentamicinpalmitate formulation prevents implant-associated osteomyelitis induced by methicillin-susceptible Staphylococcus aureus in a rat model.

Authors:  Christian Fölsch; Maike Federmann; Klaus D Kuehn; Clemens Kittinger; Stefan Kogler; Gernot Zarfel; Martina Kerwat; Steve Braun; Susanne Fuchs-Winkelmann; Jürgen R J Paletta; Philip P Roessler
Journal:  Int Orthop       Date:  2014-11-08       Impact factor: 3.075

9.  The Antibacterial Assay of Tectorigenin with Detergents or ATPase Inhibitors against Methicillin-Resistant Staphylococcus aureus.

Authors:  Dae-Ki Joung; Su-Hyun Mun; Kuang-Shim Lee; Ok-Hwa Kang; Jang-Gi Choi; Sung-Bae Kim; Ryong Gong; Myong-Soo Chong; Youn-Chul Kim; Dong-Sung Lee; Dong-Won Shin; Dong-Yeul Kwon
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-28       Impact factor: 2.629

10.  Predisposing factors for recurrence of chronic posttraumatic osteomyelitis: a retrospective observational cohort study from a tertiary referral center in Brazil.

Authors:  Luciana Souza Jorge; Alceu G Chueire; Patricia Silva Fucuta; Mauricio N Machado; Maria Gabriele L Oliveira; Marcelo A Nakazone; Mauro José Salles
Journal:  Patient Saf Surg       Date:  2017-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.